Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Her2Bi-armed ATC after Neoadjuvant Chemo in TNBC
NCT01147016Phase 2Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jul 2010
- Primary completion
- Jul 2017
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HER2Bi armed activated T-cells in triple negative breast cancer (TNBC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jul 2010; status: terminated.
02
Drugs
HER2Bi armed activated T-cells
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01147016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147016.